Association between nucleotide excision repair gene polymorphism and colorectal cancer risk

Yujie Zhang¹ | Shenshen Wu² | Xiumei Zhou¹ | Fang Huang³ | Rui Chen² | Yigang Wang¹ | Jiong Wu¹,4

¹College of Life and Medicine Sciences, Zhejiang Sci-Tech University, Hangzhou, China
²Key Laboratory of Environmental Medicine Engineering School of Public Health, Southeast University, Nanjing, China
³Department of Pathology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China
⁴Jiangsu Provincial Key Lab of Pharmaceutical Botany, Jiangsu Normal university, Xuzhou, China

Correspondence
Yigang Wang and Jiong Wu, College of Life and Medicine Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China. Emails: wangyigang43@163.com (YW) and jwu1867@hotmail.com (JW)

Funding information
This study was supported by grants from Zhejiang Provincial Natural Science Foundation of China (No. LY16H160056, LY18C070002); National Nature Science Foundation of China (No. 81803069); the Central Universities, the Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX17_0187).

Abstract
Background: The nucleotide excision repair system removes a wide variety of DNA lesions from the human genome, and plays an important role in maintaining genomic stability. Single nucleotide polymorphisms (SNPs) in nucleotide excision repair are associated with the various forms of tumor susceptibility. However, the relationship between NER polymorphism and colorectal cancer is not clear.

Methods: In this study, three candidate SNPs including ERCC4 (rs6498486), ERCC1 (rs3212986), and ERCC5 (rs17655) were analyzed in 1101 colorectal cancer patients and 1175 healthy control patients from Jiangsu province (China). Then, we performed Immunohistochemistry, qPCR, and luciferase assay to determine the potential mechanisms.

Results: The ERCC4 rs6498486 AC/CC genotypes show lower susceptibility to CRC than those carrying rs6498486 AA (Adjusted OR = 0.82, 95% CI = 0.69-0.97). However, we did not observe any association between the colorectal cancer risk and the rs3212986 (ERCC1) and rs17655 (ERCC5) polymorphisms. Immunohistochemistry, qPCR, and luciferase assay revealed that rs6498486 A > C polymorphism in the ERCC4 promoter region could lessen the expression level of ERCC4 by impacting the binding ability of the transcription factor NF-κB, thereby affecting the transcription activity of the ERCC4 gene and decreased ERCC4 gene expression.

Conclusion: In brief, our finding demonstrated that ERCC4 rs6498486 serves as a potential biomarker of CRC susceptibility for the development of colorectal cancer.

KEYWORDS
colorectal cancer, ERCC4, polymorphism, rs6498486

INTRODUCTION

Colorectal cancer is the third most common cancer and the fourth leading cause of cancer-related mortality, including more than 1.2 million new cases and 0.6 million deaths each year.¹ Although the exact pathogenesis of colorectal cancer is still unknown, environmental factors, diet, smoking, drinking, and obesity are believed to contribute to its onset.² However, not all individuals exposed to these risk factors can develop CRC, which suggests that some other factors, perhaps including gene polymorphisms, may contribute to the variation in inter-individual susceptibility to CRC.³ In addition, some studies have shown...
that individual predispositions for developing this cancer may depend on genetic changes, including changes in genes involved in the process of DNA repair, which is responsible for dealing with DNA damages.4,5 DNA repair systems play a crucial role in maintaining the genome stability, which include nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR), and double-strand break repair (DSBR).6,7 Typically, NER is listed as biochemical tool to deal with UV-induced damage such as cyclobutane-pyrimidine dimers and 6-4 pyrimidine-pyrimidone photoproduct.8 NER process had been reported to contain three steps, including damage recognition, unwinding of DNA and removal of the damaged fragment, and DNA synthesis.9,10 Several types of genes are known to be involved in NER, including ERCC1, ERCC4, and ERCC5.11,12 Genetic variations in ERCC1, ERCC4, and ERCC5 genes affect repair of bulky DNA lesions, maintenance of genomic stability, and thus affect cancer risk.13,14

NER gene polymorphisms have been extensively studied in terms of their associations with cancer risk as well as clinical outcomes in specific cancer types.15-17 The previous study had shown that polymorphisms in DNA repair genes involved in nuclear excision repair (NER) could alter the efficacy of DNA repair and thus influence individual susceptibility to colorectal cancer.18,19 Although many efforts have been made to explore the role of ERCC1, ERCC4, and ERCC5 polymorphisms in the NER pathway in the development of colorectal cancer, but it is still not identified the underling functional mechanisms between these polymorphisms and the colorectal cancer risk.20,21

In our study, we performed a case-control study on 1101 colorectal cancer patients and 1175 matched healthy controls to determine the association between DNA repair gene (ERCC1, ERCC4, and ERCC5) polymorphisms and the risk of colorectal cancer and further reveal the functional mechanisms of CRC risk.

2 | MATERIALS AND METHODS

2.1 | Study subjects

In our study, we recruited a total of 1101 newly diagnosed and histologically confirmed colorectal cancer patients, in the Jiangsu province (China) between January 2014 and October 2017. Healthy controls (1175) were randomly selected from the same hospital for physical examination. The controls were genetically unrelated to the colorectal cancer cases. The pathologic stage of colorectal cancer was assessed using the Sixth Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual. All participants signed an informed consent form, and all activities on human subjects were carried out under full compliance with the Helsinki Declaration. The study was approved by the Ethics Committee of Southeast University Affiliated Zhongda Hospital (Nanjing, China).

2.2 | DNA extraction and genotyping

Genomic DNA was extracted from whole-blood samples using the RelaxGene Blood DNA System (Tiangen Biotech). The genotypes of the rs6498486, rs3212986, and rs17655 polymorphisms were determined by TaqMan allelic identification assay equipped with A Quant Studio 6 Flex system (Applied Biosystems, Life Technologies). The loading wells without DNA were used as negative controls. 10% samples were randomly selected for verification. The accordance rate was 100%.

2.3 | Real-time PCR Assay

Total RNA was isolated from colorectal cancer tissues using Trizol reagent (Invitrogen). SYBR Green Realtime PCR (Toyobo) assay was determined by Quant Studio 6 Flex system (Applied Biosystems, Life Technologies). β-actin was chosen as internal control. Primer sequences were 5‘-TCCTCAGTTGAACTCGGTAT-3’ (forward) and 5‘-ACCCCTCACTATCATCaTCC-3’ (reverse) for ERCC4 and 5‘-ATCCGCAAAAGACCTGT-3’ and 5‘-GGGTGTAACGCAACTAAG-3’ for β-actin. Each reaction was done in triplicate.

2.4 | Immunohistochemistry

Paraffin-embedded sections fixed by formalin were dewaxed in xylene and then hydrated with ethanol gradient. Endogenous peroxidase was blocked with methanol containing 0.3% hydrogen peroxide for 30 minutes. To retrieve antigenicity, sections were boiled in 10 mmol/L citrate buffer (pH 5.8) for 30 minutes in a microwave (800 W). Next, the slices were placed in 1× CB buffer to room temperature, then transferred to TBS solution, and soaked in TBS solution for 5 minutes. Afterward, the sections were incubated at 4°C for 48 hours with primary antibodies specific for ERCC4 diluted at 1:100. After 2 days, sections were rinsed with fresh TBS solution and incubated at room temperature with horseradish peroxidase-linked secondary antibodies for 30 minutes. Finally, the sections were stained with 3,3-diaminobenzidine (DAB) substrate and counter-stained with hematoxylin. Images were recorded using a microscope. ERCC4 IHC was classified using the following scoring scheme proposed: negative or weak, ≤3; moderate, >3 but ≤6; and strong, >6.

2.5 | Cell culture

The human colorectal cancer cell line (RKO and HT-29) and HEK293T were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (Sigma, St. Louis), penicillin and streptomycin in 5% CO2 at 37°C. The cells were periodically detected and verified to be mycoplasma-free. These three cell lines were detected by short tandem repeat analysis and used within 6 months.

2.6 | Luciferase assay

293T, RKO, and HT-29 cells were seeded into 6-well plates and cultured for 16-24 h until grown to 50%-60% confluence. The ERCC4 promoter sequence containing rs6498486 A or C allele was constructed into pGL3-basic vector. They were then co-transfected with a firefly luciferase expressing plasmid (2 μg) and internal control
vector pRL-SV40 (2 μg) as an internal control, using Lipofectamine 2000 reagent (Invitrogen), in accordance with the manufacturer’s protocol. After 48 hours, we measured luciferase activity using a Dual Luciferase Reporter Assay (Promega). The relative luciferase activity was estimated by normalizing firefly luciferase activity to that of Renilla for each assay.

2.7 Statistical analysis

The Hardy-Weinberg equilibrium (HWE) was estimated in controls using the goodness-of-fit chi-square test ($\chi^2$ test). Both t test and $\chi^2$ test were applied to describe the frequency distribution of the demographic characteristic and genotype results of the SNPs between the cases and controls. Genotype and allele frequency differences between cases and controls were evaluated using logistic regression analysis, with odds ratios (OR) and 95% confidence intervals (95% CI), adjusted for age and sex. All statistical analyses were conducted using SAS. P value of less than 0.05 was considered statistically significant.

3 RESULT

3.1 Demographic and Characteristic of the study population

The control information on the subjects has been shown previously. The demographic and clinicopathological characteristics of the colorectal cancer cases and healthy controls are exhibited in Table 1. In our study, we recruited 1101 cases and 1175 controls. And the frequencies of age and gender between the cases and controls were comparable ($P > 0.05$ for age and gender). The clinical pathological data of the case patients including location, grade, depth of invasion, lymph node metastasis, distant metastasis, and TNM were also summarized in Table 1. In the case group, 540 patients were colon cancer (49.1%) and 561 patients were rectum cancer (51.0%). More intermediate grade (48.6%) was observed than low grade and high grade. 54.0% of the patient were found with negative lymph node metastasis and 39.2% presented the distant metastasis. Meanwhile, the frequencies of depth of invasion
were 4.7% (T1), 17.3% (T2), 8.5% (T3), and 69.6% (T4), respectively. 9.9% of patients were in stage I, 23.9% in stage II, 27.0% in stage III, and 39.2% in stage IV.

3.2 | Relationship between the selected polymorphisms and colorectal cancer susceptibility

The association between the four SNPs and colorectal cancer risk is shown in Table 2. The genotype distributions in control were in accordance with Hardy-Weinberg equilibrium ($P > 0.05$). The rs6498486 AC/CC genotypes were associated with decreased colorectal cancer risk (adjusted OR = 0.82, 95% CI = 0.69-0.97). However, no significant differences were observed between the risk of CRC and the rs3212986 and rs17655 polymorphisms.

3.3 | Stratified analysis of rs6498486 polymorphism and colorectal cancer risk

Stratified analysis was performed to evaluate the association between the rs6498486 polymorphism and colorectal cancer risk. As shown in Table 3, the rs6498486 AC/CC genotype suffered a significantly higher risk in the subgroups of Male (adjusted OR = 0.76, 95% CI = 0.61-0.95), negative lymph node metastasis (adjusted OR = 0.80, 95% CI = 0.66-0.99), positive distant metastasis (95% CI = 0.73, 95% CI = 0.58-0.92), and TNM IV (adjusted OR = 0.73, adjusted OR = 0.58-0.92).

3.4 | rs6498486 CC genotype decreased the ERCC4 expression levels by reducing the ERCC4 transcriptional activity

On the basis of our previous findings, we found that rs6498486 A > C polymorphism decreased the risk of colorectal cancer. Because rs6498486 polymorphism is located in the ERCC4 promoter region, we speculate that the ERCC4 rs6498486 polymorphism promoter region may affect the binding of transcription factors to promoter regions. Therefore, we analyzed the ERCC4 rs6498486 A > C polymorphism promoter region by using a bioinformatics algorithm (AliBaba2). And we found that the rs6498486 A > C polymorphism might alter the binding ability of NF-kB to the rs6498486 mutation region (Figure 1D).

### Table 2: Association between ERCC4, ERCC1, and ERCC5 polymorphisms and colorectal cancer risk

| Genotype       | Cases | Controls | P     | Adjusted OR (95% CI) |
|----------------|-------|----------|-------|---------------------|
| **ERCC4 rs6498486** |       |          |       |                     |
| AA             | 678   | 665      | 0.043 | 1                   |
| AC             | 357   | 438      | 0.80  | (0.67-0.95)         |
| CC             | 61    | 62       | 0.95  | (0.66-1.38)         |
| AC/CC          | 418   | 500      | 0.021 | 0.82 (0.69-0.97)    |
| C allele       | 0.219 | 0.241    |       |                     |
| HWE            |       |          | 0.355 |                     |
| P trend        |       |          | 0.072 |                     |
| **ERCC5 rs17655** |       |          |       |                     |
| GG             | 291   | 278      | 0.209 | 1                   |
| CG             | 556   | 586      | 0.91  | (0.74-1.11)         |
| CC             | 247   | 292      | 0.82  | (0.65-1.04)         |
| C allele       | 0.480 | 0.506    |       |                     |
| HWE            |       |          | 0.634 |                     |
| P trend        |       |          | 0.077 |                     |
| **ERCC1 rs3212986** |       |          |       |                     |
| GG             | 506   | 528      | 0.918 | 1                   |
| TG             | 478   | 515      | 0.96  | (0.81-1.15)         |
| TT             | 104   | 107      | 1.01  | (0.75-1.36)         |
| T allele       | 0.315 | 0.317    |       |                     |
| HWE            |       |          | 0.245 |                     |
| P trend        |       |          | 0.902 |                     |

Note: P-value < 0.05 was considered statistically significant (in bold).

Pearson's chi-square test for difference in distributions between the case and control groups.

The mismatch between the number of genotyping samples and a total of samples is due to the absence of samples.

*Adjusted for age, gender in the logistic regression model.
To further explore whether rs6498486 polymorphism can affect the transcriptional activity of ERCC4, we performed luciferase assay to evaluate rs6498486 transcriptional activity. We constructed two luciferase reporter vectors (Figure 1E) contain rs6498486 allele (A or C), which were transient transfected into RKO, HT-29, and 293T cells together with the Renilla luciferase plasmid. As shown in Figure 1F, the plasmid carrying C allele exhibited the significantly reduced luciferase activity than that with A allele in 293T, RKO, and HT-29 cells.

Inspired by luciferase assay, we wondered whether rs6498486 polymorphism could influence the expression level of ERCC4 through affecting the ERCC4 transcription activity. Then, we collected paraffin sections of colorectal cancer (n = 50) for each genotype and performed IHC analysis. The IHC staining of ERCC4 in colorectal cancer tissue with different rs6498486 genotypes was shown in Figure 1A,B. Results showed that the ERCC4 protein levels were downregulated in the patients carrying the AC/CC genotypes compared with those with the AA genotype. Then, we examined ERCC4 mRNA level in 88 tumor tissues from colorectal cancer patients with different genotypes. Similar to the IHC assay, compared with AA genotype, patients carrying with CC genotype showed a lower ERCC4 mRNA level (Figure 1C).

### 3.5 Expression level of ERCC4 in CRC

To further investigate the potential role of ERCC4 in CRC development, we then assessed the ERCC4 expression in 88 colorectal cancer tissue and adjacent normal tissue. As shown in Figure 2A, compared with adjacent normal tissue, a higher ERCC4 mRNA level was observed in cancer tissue. In conclusion, ERCC4 rs6498486 A > C polymorphism reduced CRC risk by downregulating ERCC4 expression.

### 4 DISCUSSION

In this work, we investigated the association between 3 SNPs (rs6498486, rs3212986, and rs17655) and colorectal cancer

| Variables                | Genotypes (cases/controls) | P            | Adjusted OR (95% CI) |
|--------------------------|----------------------------|--------------|----------------------|
|                          | AA            | AC/CC       |                      |
| Gender                   | Male          | 432/381     | 253/298              | 0.009  | 0.75 (0.60-0.93) |
|                          | Female        | 246/284     | 164/202              | 0.635  | 0.94 (0.72-1.23) |
| Location                 | Colon         | 331/666     | 206/500              | 0.079  | 0.83 (0.67-1.02) |
|                          | Rectum        | 347/666     | 212/500              | 0.050  | 0.81 (0.66-1.00) |
| Grade                    | Low           | 214/666     | 127/500              | 0.063  | 0.81 (0.64-1.03) |
|                          | Intermediate/High | 443/666   | 275/500              | 0.050  | 0.83 (0.69-1.00) |
| Depth of invasion        | T1            | 30/666      | 19/500               | 0.569  | 0.93 (0.71-1.21) |
|                          | T2            | 120/666     | 66/500               | 0.058  | 0.92 (0.72-1.17) |
|                          | T3            | 54/666      | 37/500               | 0.680  | 0.82 (0.64-1.04) |
|                          | T4            | 456/666     | 288/500              | 0.071  | 0.74 (0.59-0.92) |
| Lymph node metastasis    | N0            | 366/666     | 223/500              | 0.044  | 0.80 (0.66-0.99) |
|                          | N1            | 312/666     | 195/500              | 0.092  | 0.83 (0.67-1.03) |
| Distant metastasis       | M0            | 400/666     | 265/500              | 0.206  | 0.88 (0.73-1.07) |
|                          | M1            | 278/666     | 153/500              | 0.008  | 0.73 (0.58-0.91) |
| TNM                      | I             | 70/666      | 38/500               | 0.121  | 0.72 (0.48-1.09) |
|                          | II            | 150/666     | 110/500              | 0.866  | 0.97 (0.74-1.27) |
|                          | III           | 180/666     | 117/500              | 0.277  | 0.87 (0.67-1.12) |
|                          | IV            | 278/666     | 153/500              | 0.008  | 0.73 (0.58-0.91) |

Note: P-value < 0.05 was considered statistically significant (in bold). Pearson's chi-square test for difference in distributions between the case and control groups. Adjusted for age, gender in the logistic regression model.
susceptibility. By conducting a case-control study, we found that rs6498486 polymorphisms are associated with risk of colorectal cancer. The functional assay revealed that rs6498486 A > C inhibited the transcriptional activity of ERCC4, downregulated ERCC4 expressions, and ultimately decreased the risk of colorectal cancer (Figure 2B).

Many efforts have been made to investigate the role of ERCC1, ERCC4, and ERCC5 polymorphisms in the development of cancer. For example, a meta-analysis demonstrated that ERCC1 rs3212986 polymorphism was significantly associated with glioma risk under the following genetic models, and no association was observed between glioma risk and ERCC5 rs17655. However, Hou et al found that rs6498486 polymorphism not associated with risk of colorectal cancer and rs3212986 may be associated with colorectal cancer risk in a Chinese population. In addition, in recently published meta-analyses, Zeng et al suggests that the ERCC5 rs17655 polymorphism might contribute to genetic susceptibility to colorectal cancer. These results were inconsistent with our studies. This difference may be related to the small sample size and different ethnic backgrounds of previous researches.

Nucleotide excision repair (NER) plays a pivotal role in maintaining the stability and integrity of the genome. And NER process includes steps of damage recognition, damage demarcation and unwinding, damage incision, and new strand ligation. In the NER process, ERCC4 as an important gene could play an indispensable role in varied DNA repair system. XPF (ERCC4) is located on

**FIGURE 1** Expression of ERCC4 in colorectal cancer tissues obtained by immunohistochemical staining. Representative IHC images were obtained at 100X and 400X magnification. (A) And IHC staining scores (B) are shown. ^P < 0.05, compared with AA genotype. (C) Correlation between different rs6498486 genotypes and ERCC4 expression in colorectal cancer tissue. (D) Prediction of the binding of transcription factors to the mutation region of rs6498486 with the bioinformatics algorithm (AliBaba2). (E) Schematic description of the reporter plasmids of rs6498486. (F) Reporter plasmids with different allele of rs6498486 were transfected into RKO, HT-29, and 293T cells. Then, relative luciferase activity was detected and normalized by the internal control of renilla luciferase. The data were from three independent experiments.
chromosome 16p13.12, contains 11 exons and spans at approximately 28.2 kb, and is involved in the 5' incision made in the NER pathway. The ERCC1-XPF complex is a two subunit structure-specific nuclease. This nuclease can cleave DNA specifically near junctions between single-stranded and double-stranded DNA, where the single strand departs 5' to 3' from the junction. In addition, ERCC1-XPF is a process that removes DNA lesion caused by ultraviolet (UV) radiation exposure and by DNA damaging agents that cause covalent helix-distorting adducts. Therefore, ERCC4 is a core protein of NER pathway, and its expression affects DNA repair capacity. Nevertheless, in this study, we found a higher level of ERCC4 expression was observed in colorectal cancer tissue. We speculated that a large amount of DNA damage was accumulated in the tumor, and cells need expressed more ERCC4 proteins to repair these damages, which led to the protein level of ERCC4 increased in the colorectal cancer tissues. This conjecture explained that how
rs6498486 A > C polymorphism involved in colorectal cancer risk by decreased ERCC4 expression.

The nuclear factor-kappaB (NF-kB) is a family of regulatory proteins controlling many biological processes, including: proliferation, survival, apoptosis, invasion, and metastasis in many normal and cancerous cell types.\(^{30-32}\) When the NF-kB pathway is activated, the released p65/p50 NF-kB dimers translocate from the cytoplasm to the nucleus where they bind to specific DNA sequences and promote transcription of target genes.\(^{32,33}\) The NF-kB signaling pathway has been shown to promote the progression of different cancers, including breast cancer, prostate cancer, pancreatic cancer, and colorectal cancer.\(^{34,35}\) In our study, we found that rs6498486 A > C polymorphism may alter the binding of transcription factors (NF-kB) to promoter regions. Similarly, luciferase assay demonstrated that rs6498486 polymorphism affects the transcription activity of the ERCC4 gene. However, further functional experiments are required to demonstrate the ERCC4 rs6498486 polymorphism might change the binding affinity of the transcription factor NF-kb to the rs6498486 mutation region.

In conclusion, our results revealed that rs6498486 A > C polymorphism could alter the transcription activity of ERCC4 gene, thereby changing the expression level of ERCC4. However, further functional researches are required to verify our result.

**AUTHOR CONTRIBUTIONS**

All authors contributed significantly to this work. Yujie Zhang and Shenshen Wu conceived and designed the study; Xiumei Zhou, Fang Huang, Rui Chen, Jiong Wu, and Yigang Wang analyzed the data; Yujie Zhang, Shenshen Wu, Jiong Wu, and Yigang Wang created all tables and figures; Yujie Zhang drafted the manuscript; Shenshen Wu, Jiong Wu, and Yigang Wang made critical revision of the manuscript. All authors read and approved the final manuscript. Xiumei Zhou, Fang Huang, and Rui Chen monitored the study.

**INFORMED CONSENT**

In this study, all activities on human subjects were carried out under full compliance with the Helsinki Declaration, and all individual participants signed an informed consent form.

**ORCID**

Yujie Zhang https://orcid.org/0000-0002-1882-8127

**REFERENCES**

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. *Ca-Cancer J Clin*. 2011;61(2):69-90.
2. Gao X, Huang M, Liu L, et al. Insertion/deletion polymorphisms in the promoter region of BRM contribute to risk of hepatocellular carcinoma in Chinese populations. *PLoS ONE*. 2013;8(1):e55169.
3. Migliore L, Migheli F, Spisni R, Coppede F. Genetics, Cytogenetics, and Epigenetics of Colorectal Cancer. *J Biomed Biotechnol.* 2011;2011:1-19.
4. Segui N, Mina LB, Lázaro C, et al. Germline Mutations in FAN1 Cause Hereditary Colorectal Cancer by Impairing DNA Repair. *Gastroenterology*. 2015;149(3):563-566.
5. Dzikzi L, Dzikzi A, Mik M, Majsterek I, Kabzinski J. Modulation of Colorectal Cancer Risk by Polymorphisms in 51Gln/His, 64lle/Val, and 148Asp/Glu of APEX Gene; 23Gly/Ala of XPA Gene: and 689Ser/Arg of ERCC4 Gene. *Gastroenterol Res Pract*. 2017;2017:3840243.
6. Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. *Environ Mol Mutagen*. 2017;58(5):235-263.
7. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. *Annu Rev Biochem*. 2004;73:39-85.
8. Gillet LC, Scharer OD. Molecular mechanisms of mammalian global nucleotide excision repair. *Chem Rev*. 2006;106(2):253-276.
9. Saldivar JS, Wu XF, Follen M, Gershenson D. Nucleotide excision repair pathway review I: Implications in ovarian cancer and platinum sensitivity. *Gynecol Oncol*. 2007;107(1):556-571.
10. Shell SM, Zou Y. Other proteins interacting with XP proteins. *Adv Exp Med Biol*. 2008;637:103-112.
11. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. *Mol Cell Biol*. 2000;20(21):7980-7990.
12. Rao KS, SureshKumar S, Umamaheswaran G, et al. Frequency distribution of DNA repair genes ERCC1 and ERCC2 polymorphisms in South Indian healthy population. *Environ Toxicol Pharmac.* 2014;38(2):480-488.
13. Kaur S. Human DNA ligase i (lgi) gene and risk of cervical cancer in North Indian women. *Exp Oncol*. 2013;35(3):226-228.
14. Li Y, Liu Z, Liu H, et al. ERCC1 and ERCC2 variants predict survival in gastric cancer patients. *PLoS ONE*. 2013;8(9):e71994.
15. Wu XF, Zhao H, Wei QY, et al. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. *Carcinogenesis*. 2003;24(3):505-509.
16. Marín MS, Lopez-Cima MF, Garcia-Castro L, Pascual T, Marron MG, Tardon A. Poly (AT) polymorphism in intron 11 of the XPC DNA repair gene enhances the risk of lung cancer. *Cancer Epidemiol Biomar*. 2004;13(11):1788-1793.
17. Spitz MR, Wu XF, Wang YF, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. *Cancer Res*. 2001;61(4):1354-1357.
18. Mucha B, Przybylowska-Sygit K, Dzikzi AJ, Dzikzi L, Sygit A, Majsterek I. Association of Thr241met polymorphism of Xrcc3 gene with risk of colorectal cancer in the polish population. *Pol J Pathol*. 2013;64(3):185-190.
19. Yousef A, Shomaf M, Berger S, et al. Allele and genotype frequencies of the polymorphic methylenetetrahydrofolate reductase and colorectal cancer among Jordanian population. *Asian Pac J Cancer Prev*. 2013;14(8):4559-4565.
20. Hou R, Liu Y, Feng YE, et al. Association of single nucleotide polymorphisms of ERCC1 and XPF with colorectal cancer risk and interaction with tobacco use. *Gene*. 2014;548(1):1-5.
21. Kong JY, Liu Z, Cai F, Xu XC, Liu J. Relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer in China. *Clinics*. 2018;73:e455.
22. Wu S, Meng Q, Zhang C, et al. DR4 mediates the progression, invasion, metastasis and survival of colorectal cancer through the Sp1/NF1 switch axis on genomic locus. *Int J Cancer*. 2018;143(2):289-297.
23. Qian TD, Zhang B, Qian CS, He YW, Li YH. Association between common polymorphisms in ERCC gene and glioma risk A meta-analysis of 15 studies. *Medicine*. 2017;96(20):e6832.
24. Zeng Y, Wei L, Wang J-Y, Liu C. Genetic Association between ERCC5 rs17655 polymorphism and colorectal cancer risk: evidence based on a meta-analysis. *Asian Pac J Cancer Prev*. 2015;16(13):5565-5571.
25. Sun YN, Tan LJ, Li HJ, Qin XW, Liu JT. Association of NER pathway gene polymorphisms with susceptibility to laryngeal cancer in a Chinese population. Int J Clin Exp Pathol. 2015;8(9):11615–11621.
26. Kamileri I, Karakasilioti I, Garinis GA. Nucleotide excision repair: new tricks with old bricks. Trends Genet. 2012;28(11):566–573.
27. Ng J, Vermeulen W, van der Horst G, et al. A novel regulation mechanism of DNA repair by damage-induced and RAD23-dependent stabilization of xeroderma pigmentosum group C protein. Gene Dev. 2003;17(13):1630–1645.
28. Liu P, Siciliano J, White B, et al. Regional mapping of human DNA excision repair gene Ercc4 to chromosome-16p13.13-P13.2. Mutagenesis. 1993;8(3):199–205.
29. Scharer OD. Nucleotide excision repair in eukaryotes. Cold Spring Harb Perspect Biol. 2013;5(10):a012609.
30. Siomek A. NF-kappaB signaling pathway and free radical impact. Acta Biochim Pol. 2012;59(3):323–331.
31. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kB activation: From bench to bedside. Exp Biol Med. 2008;233(1):21–31.
32. Nurmi A, Lindsberg PJ, Koistinaho M, et al. Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke. 2004;35(4):987–991.
33. Ridder DA, Schwaninger M. NF-kappaB signaling in cerebral ischemia. Neuroscience. 2009;158(3):995–1006.
34. Gambhir S, Vyas D, Hollis M, Aekka A, Vyas A. Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies. World J Gastroentero. 2015;21(11):3174–3183.
35. Wang W, Nag SA, Zhang R. Targeting the NFkappaB signaling pathways for breast cancer prevention and therapy. Curr Med Chem. 2015;22(2):264–289.

How to cite this article: Zhang Y, Wu S, Zhou X, et al. Association between nucleotide excision repair gene polymorphism and colorectal cancer risk. J Clin Lab Anal. 2019;33:e22956. https://doi.org/10.1002/jcla.22956